1

2

3
Ji Qun Sheng, Arnold Lee D, Mulvihill Mark Joseph: Combination of igfr inhibitor and anti-cancer agent. Osi Pharmaceuticals, Ji Qun Sheng, Arnold Lee D, Mulvihill Mark Joseph, BLAKEY Alison, July 5, 2007: WO/2007/075554 (54 worldwide citation)

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGFlR inhibitor compound of Formula I combination, with or withou ...


4

5
Arnold Lee D, Chen Xin, Dong Hanping, Garton Andrew, Mulvihill Mark Joseph, Smith Colin Peter Sambrook, Thomas Gerard Hugh, Krulle Thomas Martin, Wang Jing: Fused heterobicyclic kinase inhibitors. Osi Pharmaceutical, Arnold Lee D, Chen Xin, Dong Hanping, Garton Andrew, Mulvihill Mark Joseph, Smith Colin Peter Sambrook, Thomas Gerard Hugh, Krulle Thomas Martin, Wang Jing, RAFA Michael J, July 26, 2007: WO/2007/084667 (18 worldwide citation)

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the ...


6
Arnold Lee D, Ji Qun Sheng, Mulvihill Mark Joseph: Combination of igfr inhibitor and anti-cancer agent. Osi Pharmaceuticals, Arnold Lee D, Ji Qun Sheng, Mulvihill Mark Joseph, NGUYEN Kim T, June 26, 2008: WO/2008/076143 (11 worldwide citation)

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anticancer agent and an IGFlR inhibitor compound of Formula (I) combination, with or without a ...


7

8
Hirst Gavin C, Calderwood David, Wishart Neil, Rafferty Paul, Ritter Kurt, Arnold Lee D, Friedman Michael M: Pyrazolopyrimidines as therapeutic agents. Basf Aktiengesellschaft, Hirst Gavin C, Calderwood David, Wishart Neil, Rafferty Paul, Ritter Kurt, Arnold Lee D, Friedman Michael M, DECONTI Giulio A, March 22, 2001: WO/2001/019829 (2 worldwide citation)

The present invention provides compounds of Formula (I), including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R¿a?, R¿2?, R¿3? are defined as described herein and their use as protein Kinase inhibitors.


9
Hirst Gavin C, Arnold Lee D, Burchat Andrew, Wishart Neil, Calderwood David, Wada Carol K, Michaelides Michael R, Ji Zhiqin, Muckey Melanie: Kinase inhibitors. Abbott Laboratories, Hirst Gavin C, Arnold Lee D, Burchat Andrew, Wishart Neil, Calderwood David, Wada Carol K, Michaelides Michael R, Ji Zhiqin, Muckey Melanie, O BRIEN Gayle B, October 2, 2003: WO/2003/080064 (2 worldwide citation)

The present application is directed to pyrazolopyrimidine and furopyrimidine analogs of the formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.


10
Hirst Gavin C, Rafferty Paul, Ritter Kurt, Calderwood David, Wishart Neil, Arnold Lee D, Friedman Michael M: Pyrazolopyrimidines as therapeutic agents. Abbott & Co Kg, Hirst Gavin C, Rafferty Paul, Ritter Kurt, Calderwood David, Wishart Neil, Arnold Lee D, Friedman Michael M, CONWAY John D, October 3, 2002: WO/2002/076986 (1 worldwide citation)

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, and R3 are defined as described herein.